forecast

Long-run margin profile closer to medtech than biotech

Because the company no longer does discovery research, its R&D intensity should settle near 5 to 7 percent of revenue like medtech rather than the 20 to 25 percent typical of biotech, yielding a medtech-style P&L.

forecastpending

Speaker

Bill

Evidence Quote

“We're not doing discovery research, so it's not going to be the 20, 25% that you see in biotech”

Source

Novocure: Using Physics to Fight Cancer— Business Breakdowns
Created: 11/19/2026, 2:27:17 AM

Your notes

Loading notes...